Korro Bio, Inc.

NASDAQ:KRRO

Biotechnology

Healthcare
$12.44 +15.88%

+$1.76 today

Market cap
$170.75M
Beta
2.10
P/E (TTM)
-1.3
EPS (TTM)
-$9.79
52W Low $5.20High $55.89

Volume 0.16M

Average 0.15M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$78.56M

FY 2025 · Annual

Investing Cash Flow

$43.99M

FY 2025 · Annual

Financing Cash Flow

$685,000.00

FY 2025 · Annual

-99.0% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(21.96M)(58.03M)(81.17M)(83.58M)(117.26M)
Depreciation & Amortization1.6M2.51M3.63M3.57M3.79M
Deferred Income Tax0(145K)000
Stock-Based Compensation807K1.14M2.38M4.46M7.66M
Change in Working Capital904K(633K)4.28M13.59M(4.43M)
Accounts Receivables000(1.7M)727K
Inventory00000
Accounts Payables56K1.76M3.1M(1.34M)(2.31M)
Other Working Capital848K(2.39M)1.18M16.63M(2.84M)
Other Non-Cash Items(13.44M)1.51M3.6M1.89M31.68M
Operating Cash Flow(32.09M)(53.65M)(67.28M)(60.07M)(78.56M)
Capital Expenditures(4.45M)(5.21M)(7.84M)(17.9M)(518K)
Acquisitions (Net)00000
Purchases of Investments(35.07M)(37.21M)0(146.35M)(26.19M)
Sales of Investments053.49M19M40.9M70.7M
Other Investing Activities13K0000
Investing Cash Flow(39.5M)11.06M11.16M(123.35M)43.99M
Debt Repayment00000
Common Stock Issued28K62K117.25M67.39M685K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(2K)(44K)25.05M1.97M0
Financing Cash Flow115.95M18K187.76M69.36M685K
Effect of Forex Changes000(4K)64K
Net Change in Cash44.35M(42.57M)131.64M(114.07M)(33.82M)
Free Cash Flow(36.54M)(58.86M)(75.12M)(77.98M)(79.08M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$117.3M
+ D&A$3.8M
+ Stock-Based Comp$7.7M
+ Deferred Tax$0
- Working Capital-$4.4M
+ Other Non-Cash$31.7M
= Operating Cash Flow-$78.6M
- Capex-$518.0K
= Free Cash Flow-$79.1M

Analysis

FY2025 free cash flow is -$79.1M. FCF conversion is 67.4% of net income. Operating cash flow was -$78.6M, with capex of -$518.0K. The largest bridge item is Other Non-Cash at $31.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
SC 13GSC 13G filingNov 12, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
SC 13G/ASC 13G/A filingOct 27, 2026

Does KRRO generate free cash flow?

Korro Bio, Inc. (KRRO) generated -$79.08M of free cash flow in fiscal 2025.

How much operating cash flow does KRRO produce?

Operating cash flow was -$78.56M, before capital expenditures of $518,000.00.